2 deals
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.